Overview

A Multicentric Phase II Trial Evaluating MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
Multicentric, prospective, multi-indication, single-treatment arm, open-label phase II trial assessing the efficacy of MEDI5752
Phase:
Phase 2
Details
Lead Sponsor:
Institut Bergonié
Collaborators:
AstraZeneca
National Cancer Institute, France